News for CRISPR Therapeutics AG (0VRQ.L)

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $39.11, marking a +1.48% move from the previous day.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day.

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene therapy product for treating sickle cell disease, Casgevy, faces market hurdles. However, recent political developments, including both at the White House and the Food and Drug Administration (FDA), have paved the way for CRISPR to secure payment for Casgevy and advance new treatments. As a result, I am bullish on CRISPR’s prospects in the short term, although some doubts

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $37.77, representing a -0.03% change from its previous close.

Bank of America has revised its price target for Crispr Therapeutics (CRSP), reducing it to $80 from the previous $86, although it maintains a Buy rating on the

In the latest market developments, Sealsq Corp (LAES) emerged as a prominent name in the financial sector with a significant surge in its indicative borrow rate

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $34.26, moving -1.81% from the previous trading session.

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

CRISPR Therapeutics AG (NASDAQ:CRSP) Annual Needham Virtual Healthcare Conference Call April 8, 2025 12:45 PM ETCompany ParticipantsSam Kulkarni - Chief...

On Friday, April 4, 2025, Cathie Wood-led Ark Invest made substantial trades involving several prominent companies including Coinbase Global Inc. COIN, Amazon.c...

CRISPR Therapeutics AG (CRSP) closed at $32.65 in the latest trading session, marking a -0.03% move from the prior day.

Summary CRISPR Therapeutics AG (CRSP), a pioneering biopharmaceutical company specializing in gene-based medicines, announced on April 3, 2025, that its senior

**media[578192]**

CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $41.22, indicating a +0.12% shift from the previous trading day.

On Thursday, March 20, 2025, Cathie Wood's Ark Invest purchases $2.2M in Tesla shares despite Cybertruck recalls and financial concerns, while simultaneously selling $2.7M of Meta stock amid the company's privacy challenges.

CRISPR Therapeutics AG (CRSP) closed at $41.17 in the latest trading session, marking a -1.84% move from the prior day.

Cathie Wood's Ark Invest sold $4.3 million worth of Meta shares on Wednesday, March 19, 2025, despite the company's Llama AI reaching 1 billion downloads.